We are live on ! Find out more
RSLS

ReShape Lifesciences Inc. Common Stock
RSLS

Delisted

RSLS was delisted on the 28th of December, 2018.

Back to rankings

12 hedge funds and large institutions have $9.13M invested in ReShape Lifesciences Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

55% more capital invested

Capital invested by funds: $5.88M → $9.13M (+$3.24M)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 → 12 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.27%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
+$3.41M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$398K
3
Citadel Advisors
Citadel Advisors
Florida
+$28.6K
4
Northern Trust
Northern Trust
Illinois
+$28.6K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$324K
2
Goldman Sachs
Goldman Sachs
New York
-$33K
3
Morgan Stanley
Morgan Stanley
New York
-$3.18K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NLVP
1
New Leaf Venture Partners
New York
$3.77M – – –
SHI
2
SV Health Investors
Massachusetts
$3.26M +$3.41M +1,072 New
IBT
3
International Biotechnology Trust
United Kingdom
$1.14M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$781K +$398K +125 +95%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$38K – – –
US Bancorp
6
US Bancorp
Minnesota
$36K – – –
BlackRock
7
BlackRock
New York
$29K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$28K +$28.6K +9 New
Northern Trust
9
Northern Trust
Illinois
$27K +$28.6K +9 New
UBS Group
10
UBS Group
Switzerland
$3K – – –
Morgan Stanley
11
Morgan Stanley
New York
$2K -$3.18K -1 -50%
Parallax Volatility Advisers
12
Parallax Volatility Advisers
California
$2K – – –
FANJ
13
Financial Architects (New Jersey)
New Jersey
$1K – – –
SWM
14
SeaCrest Wealth Management
New York
$1K – – –
AFM
15
Anson Funds Management
Texas
– -$324K -104 Closed
Goldman Sachs
16
Goldman Sachs
New York
– -$33K -11 Closed
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
– -$1K – –

RSLS Hedge Fund Activity: Q1 2018 in Review

12 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q1 2018, worth a combined $9.13M — up 55% from $5.88M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RSLS positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was SV Health Investors, opening a new position worth an estimated $3.41M. The largest seller was Anson Funds Management, exiting entirely with an estimated $324K sold.

  • 12 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q1 2018, up from 11 in Q4 2017.
  • Funds reported $9.13M of ReShape Lifesciences Inc. Common Stock stock for Q1 2018, up 55% quarter-over-quarter.
  • 3 funds opened new ReShape Lifesciences Inc. Common Stock positions in Q1 2018 and 2 closed out, a net change of +1 holder.
  • The largest ReShape Lifesciences Inc. Common Stock buyer in Q1 2018 was SV Health Investors, an estimated $3.41M added.
  • The largest ReShape Lifesciences Inc. Common Stock seller in Q1 2018 was Anson Funds Management, an estimated $324K sold.

Based on aggregated 13F filings for Q1 2018.